Psychedelics Conference Draws Diverse Crowd, Highlights Shifting Perceptions

More than 600 individuals gathered in Austin, Texas, for Dave Asprey's inaugural "Beyond Psychedelics Conference," an event exploring the growing mainstream interest in psychedelics for mental health and cognitive enhancement. The conference, held from October 12-14, 2026, featured neuroscientists, researchers, wellness gurus, and individuals seeking to use substances like psilocybin and ayahuasca for personal transformation.

Rick Doblin, founder of the Multidisciplinary Association for Psychedelic Studies (MAPS), noted the significant shift in the field's perception. "It’s astonishing to me how legitimate it looks these days," Doblin stated backstage at the event. Major institutions such as Johns Hopkins and Mount Sinai are now investigating psychedelic applications, and investors have injected substantial capital into the burgeoning industry. Legal landscapes are also evolving, with some states and cities decriminalizing certain psychedelics and others establishing regulated pathways for psilocybin-assisted therapy.

Even governmental interest has surfaced. In April 2026, President Donald Trump signed an executive order to accelerate the review of treatments for serious mental illnesses, including treatment-resistant depression and PTSD. Asprey, a proponent of biohacking, framed psychedelics as a tool for "enhancement" rather than mere "optimization."

The conference offered various access levels, with tickets ranging from $599 for a one-day pass to $1,699 for VIP access. Attendees participated in talks on emerging treatments, scientific developments, and market trends, while also engaging with "consciousness tech" and alternative practices like breathwork and Indigenous rituals.

Many attendees shared personal accounts of using psychedelics to overcome long-standing mental health struggles and trauma that conventional treatments had failed to address. "Plant medicine helped me get there," one attendee, who experienced severe PTSD, reported. Researchers at the conference discussed the potential therapeutic benefits of psychedelics, though they also cautioned that much remains unknown about their mechanisms, optimal use, and risks.

Dr. David Rabin, a neuroscientist specializing in psychedelic-assisted therapy, highlighted ketamine as one of the few legally prescribed psychedelic-like substances in the U.S. He emphasized the importance of combining ketamine with psychotherapy to avoid dependency and promote self-healing.

Beyond therapeutic discussions, the conference featured a marketplace with vendors offering a range of products. Azul Chocolates provided psilocybin-infused treats, while PLÜR Beyond Molly offered 5-MAPB capsules, marketed as a safer alternative to MDMA. Companies like Guides Collective connected attendees with facilitators and therapists for guided psychedelic experiences. Luxury resorts also promoted psychedelic retreats in international locations.

For those seeking altered states without illicit substances, the conference included sessions on quantum breathwork and neurofeedback training, which aim to influence the nervous system and brainwave activity respectively to promote emotional regulation and cognitive enhancement.

The diverse attendance, ranging from professionals to older adults, underscored the expanding appeal of psychedelics beyond traditional counterculture circles. An 85-year-old attendee shared her transformative experience with plant medicine, which she began at age 78, finding it brought her "Love. Peace. Respect."